The CASP3 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal colorectal adenocarcinoma population designed for loss-of-function studies of the CASP3 gene, which encodes the executioner caspase-3. This polyclonal knockout model was generated via CRISPR/Cas9-mediated gene disruption in the HT29 human cell line, yielding a heterogeneous pool of edited cells suitable for pooled functional assays and pathway interrogation. The product provides a versatile system for investigators to examine caspase-3-dependent apoptosis signaling without the clonal selection constraints of monoclonal knockouts, enabling robust representation of the full editing spectrum across the population.
HT29 is a well-characterized human colorectal adenocarcinoma cell line with epithelial morphology, originally derived from a primary colon tumor. These cells are widely employed in intestinal cell biology and colorectal cancer research due to their ability to form polarized monolayers and their relevance as a model for studying tumor cell signaling, drug response, and apoptosis regulation. The HT29 background offers a physiologically pertinent context for dissecting the role of CASP3 in colon cancer, particularly given that colorectal tumors frequently exhibit dysregulated apoptotic programs and resistance to death receptor- or chemotherapy-induced cell death.
Caspase-3 functions as a central executioner caspase that is proteolytically activated by initiator caspases, such as caspase-8 and caspase-9, in response to apoptotic stimuli transmitted through extrinsic death receptors (Fas, TNF-R1) or intrinsic mitochondrial signals (cytochrome c, Apaf-1). Once activated, caspase-3 cleaves a wide array of cellular substrates??including PARP, ICAD, lamin A, fodrin, gelsolin, and PAK2??orchestrating the hallmark biochemical and morphological changes of apoptosis. Its activity is modulated by interactions with inhibitor of apoptosis proteins (XIAP, Survivin, c-IAP1/2) and antagonized by the mitochondrial-derived protein Smac/DIABLO. CASP3 also integrates signals from upstream regulators such as Bcl-2 family members (Bax, Bak, Bim) and participates in crosstalk with the p53 and PI3K/Akt pathways, making it a critical node in life-or-death decisions.
In the HT29 colorectal adenocarcinoma context, CASP3 disruption allows interrogation of apoptosis resistance mechanisms inherent to colon cancer cells, including the contributions of caspase-3 to chemoresistance and tumor cell survival. The polyclonal knockout pool is particularly suited for studying how heterogeneous CASP3 deficiency influences responses to death receptor ligands (FasL, TRAIL) or conventional chemotherapeutics, and for evaluating compensatory signaling through parallel pathways such as PI3K/Akt. This model supports the exploration of synthetic lethal interactions and the identification of molecular determinants that dictate sensitivity or resistance to pro-apoptotic therapies in colorectal cancer.
The CASP3 knockout HT29 polyclonal cells enable a range of research applications, including drug screening for apoptosis-inducing agents, mechanistic studies of cell death signaling, and evaluation of anti-cancer compounds targeting the apoptotic machinery. Investigators can employ Western blotting for CASP3 and cleaved substrates (e.g., PARP), caspase-3 activity assays, Annexin V/PI flow cytometry, TUNEL assays, and cell viability measurements (MTS/MTT) to validate functional outcomes. Additional downstream analyses such as RNA-seq and immunofluorescence for cleaved caspase-3 facilitate transcriptomic profiling and spatial assessment of apoptosis. For further information, please contact Ascent Research.
